Sangamo Therapeutics (SGMOQ) Revenue (2010 - 2025)

Sangamo Therapeutics' Revenue history runs 16 years deep, the most recent figure standing at $14.2 million for Q4 2025.

• On a quarterly basis, Revenue rose 118.89% year-over-year to $14.2 million in Q4 2025; TTM through Dec 2025 was $39.6 million, a 30.3% decrease from a year earlier, with the FY2025 full-year figure at $39.6 million, down 31.57% from the prior year.
• Revenue climbed to $14.2 million in Q4 2025 per SGMOQ's latest filing, from $581000.0 in the prior quarter.
• Across five years, Revenue topped out at $158.0 million in Q1 2023 and bottomed at $356000.0 in Q2 2024.
• The 5-year median for Revenue is $22.3 million (2021), against an average of $24.7 million.
• Across the five-year window, Revenue plunged 99.7% in 2024 and surged 5042.13% in 2025, its largest moves.
• Year by year, Revenue stood at $28.0 million in 2021, then declined by 2.7% to $27.2 million in 2022, then sank by 92.5% to $2.0 million in 2023, then surged by 218.32% to $6.5 million in 2024, then soared by 118.89% to $14.2 million in 2025.
• Per Business Quant, the three latest SGMOQ Revenue figures stand at $14.2 million (Q4 2025), $581000.0 (Q3 2025), and $18.3 million (Q2 2025).